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Latent class growth analysis
A B S T R A C T
Background: Forty-percent of the variance in psychological treatment outcomes is estimated to be explained by
symptom change by the third treatment session. However, change may not be uniform across patient groups and
symptom domains. This study aimed to identify subgroups of patients with different trajectories of depression
and anxiety symptom change during psychological therapy and identify baseline patient characteristics asso-
ciated with these trajectories.
Methods: 4394 patients attending two psychological treatment services completed sessional, self-report de-
pression and anxiety measures. Trajectories of symptom change were investigated using latent class growth
analysis. Multinomial logistic regression was used to explore associations between baseline patient character-
istics and trajectory classes.
Results: A number of distinct trajectories were identified. Anxiety symptom trajectories could be distinguished
by the third treatment session, but for depression symptoms there was a class displaying limited change until
session six followed by rapid improvement in symptoms thereafter. Compared to the non-responding trajec-
tories, depression and anxiety trajectories indicating treatment response were associated with lower baseline
severity, better social functioning and lower incidence of phobic anxiety, but not with medication prescription
status.
Limitations: Data came from two services, so wider generalisability is unknown. Predictors were limited to data
routinely collected in the services; unmeasured factors may have improved the prediction of trajectories.
Conclusions: Baseline characteristics and symptom change early in therapy can help identify different trajec-
tories of symptom change. This knowledge could aid clinical decision making and help improve treatment
outcomes. By ignoring distinct trajectories, clinicians may incorrectly consider patients as “not-on-track” and
unnecessarily change or end therapy that would otherwise benefit patients.
1. Introduction
Being able to predict the outcome of treatment may be of significant
benefit to patients, clinicians and health care services (Lambert et al.,
2001a). However, clinicians tend to be poor judges of the probability of
patients recovering (Harmon et al., 2007), often overestimating the
likelihood of positive outcomes for their own patients (Walfish et al.,
2012). Measuring changes in symptom severity during the early stages
of treatment has allowed for greater accuracy in predicting treatment
outcomes, and has been used to provide clinicians with feedback on the
probability of those outcomes to guide their decision making. For
example, providing feedback to clinicians about whether their patients
are “on track” or “not-on-track” during therapy has led to improved
post-treatment outcomes in university based counselling services in the
USA (Bybee et al., 2007; Lambert and Shimokawa, 2011). Further, a
meta-analysis of controlled studies showed that when feedback based
on expected symptom change is provided, more patients recover and
the rate of patients experiencing a clinical deterioration during therapy
reduces by half among the “not-on-track” patients (Shimokawa et al.,
2010).
A consistent pattern of symptom change during psychological
treatment has typically shown a rapid improvement between sessions
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two and four which levels out as the number of treatment sessions in-
creases (Cuijpers et al., 2013; Kopta et al., 1994). Up to 40% of the
variance in treatment outcomes has been attributed to symptomatic
change by the third therapy session (Lambert, 2013). Meta-analyses of
pharmacological interventions have reported similar findings, with re-
latively large decreases in symptom severity within the first two weeks
of treatment being predictive of eventual treatment response (Gorwood
et al., 2013; Szegedi et al., 2009).
Overall, outcome feedback systems have demonstrated that identi-
fying standard expected response trajectories and informing clinicians
of individual patient's expected treatment response based on these
trajectories, can lead to improved patient outcomes. However, the ef-
fect sizes from these studies are relatively modest. One potential reason
for this is that studies using therapist feedback systems to-date have
compared participating patients to an overall averaged response curve
across all participants (e.g. Lambert et al., 2001a). It is possible that
some patients may follow different trajectories of symptom change, and
thus using a singular response curve to compare all patients may reduce
the predictive strength of these systems. For example, previous analyses
of depression symptom trajectories during a randomised controlled trial
of cognitive therapy indicated that although 50% of participants follow
a linear, or log-linear function, a small proportion (16%) showed no
change before a sudden drop between weeks four and five
(Vittengl et al., 2013).
Given that most studies of symptom change to-date have used a cut-
point at two weeks (pharmacological) or three sessions (psychological)
of treatment, distinguishing between these potentially different groups
of patients may not have been possible. If there are distinctly different
trajectories of change, identifying these and using them as a basis for
comparison should enable clinicians to more accurately predict any
new patient's likely prognosis. Further, identifying predictors of the
different trajectories of change, at different stages of therapy, ideally at
intake, would provide crucial information for guiding treatment deci-
sions.
The identification of patient subgroups for whom trajectories of
symptom change differ requires modelling techniques that can identify
distinct sub-populations within the sample (Rubel et al., 2015;
Spinhoven et al., 2016). Growth mixture modelling (GMM) offers one
method of identifying such subgroups (Muthén, 2001; Muthén et al.,
2002) and has been used to identify responders (and non-responders) to
antidepressant medication (Gueorguieva et al., 2011), as well as classes
of change during psychological treatments (e.g. Stulz et al., 2007;
Vittengl et al., 2013). More specifically classes have been identified that
made sudden symptomatic improvements during cognitive therapy,
recruited in a US outpatient psychology service (Tang and
DeRubeis, 1999), and early responding trajectories in the first three
sessions of psychotherapy delivered across a range of settings
(Rubel et al., 2015). However, such techniques have yet to be applied to
psychological treatments offered solely within primary care settings,
and most previous studies risk being underpowered to reliably detect
distinct classes.
The establishment of the Improving Access to Psychological
Treatment (IAPT) (Clark, 2011) services in England provides an op-
portunity to explore trajectories of symptom change in a large natur-
alistic cohort. The sessional collection of symptom measures is man-
datory in these services. IAPT services deliver evidence-based
psychological treatments as part of a stepped care model; low-intensity
(LI) brief interventions (e.g. self-help) typically delivered for less severe
presentations and high-intensity (HI) formal psychological interven-
tions (e.g. cognitive behavioural therapy (CBT)) typically delivered for
more severe presentations (Clark, 2018). Approximately 965,000 pa-
tients entered IAPT treatment in the 2016–17 financial year (NHS
Digital, 2017), and with the numbers of patients treated increasing each
year (e.g. Clark, 2018), the ability to predict likely symptom change
during IAPT treatments could help optimise service provision. Knowl-
edge regarding recovery and likely post-treatment symptom scores
could inform treatment planning, especially when considering that in-
complete recovery is a strong predictor of both relapse and returning to
the services for further treatment (Ali et al., 2017; Buckman et al.,
2018b). Further, following more defined trajectories of symptom
change has been found to be associated with better long term outcomes
(Vittengl et al., 2016) which could further guide treatment decision
making.
The use of feedback to clinicians of the type described in previous
studies (e.g. Lambert et al., 2001a), has been tested in a recent multi-
centre randomised controlled trial conducted in IAPT services
(Delgadillo et al., 2018). The study found that when patients were “not-
on-track” providing clinicians with feedback helped reduce the risk of
poor outcomes compared to patients of clinicians without access to
feedback. However, methods to identify distinct trajectories rather than
just the mean symptom change may provide greater accuracy in pre-
dicting treatment outcomes. Previous studies have reported high cor-
relations between depression and anxiety symptom scores in patients
attending treatment services (Ryan et al., 2013) and have suggested
that the overall trajectory of depression and anxiety change is similar
for adolescents receiving psychological therapy (Queen et al., 2014).
However previous research has not explored whether the distinct tra-
jectories of change are similar across symptom measures in adults at-
tending psychological treatment services.
The aims of this study are to model the differing trajectories of
change in both depression and anxiety symptoms in patients receiving
HI psychological treatments in two psychological treatment services,
and to assess whether there are pre-treatment patient characteristics
predictive of these trajectories.
2. Method
2.1. Services
Data were provided by two IAPT services in London. IAPT services
provide evidence-based psychological treatments for common mental
health disorders such as depression and anxiety disorders. Whilst
formal diagnoses are not necessarily made in IAPT services, clinicians
are trained to identify what is referred to as the “presenting problem”,
which is used as a diagnosis for selecting an appropriate treatment
protocol (Clark, 2018). These treatment protocols are recommended by
the National Institute for Health and Care Excellence (NICE) and form
part of the curriculum for courses training IAPT professionals nation-
ally, meaning all patients with particular conditions should be receiving
the same NICE recommended interventions across all IAPT services.
Information on treatment protocol adherence is not routinely collected
by IAPT services and therefore was not available for the current study,
although services are expected to operate their own means of checking
adherence through practice and supervision.
2.2. Participants
Patients were included in the study if they received HI psychological
therapy (e.g. CBT, counselling and interpersonal psychotherapy) be-
tween September 2008 and August 2013, provided depressive and an-
xiety symptom measure scores on at least three occasions, and were
above the cut-off for “caseness” on either or both the symptom measure
(s) pre-treatment (see measures section below). Patients were excluded
if they did not attend at least three sessions of treatment or were below
caseness on both symptom severity measures at initial assessment. A
minimum of three treatment sessions was required in order to model
trajectories of symptom change.
2.3. Measures
Patient Health Questionnaire 9-item version (PHQ-9; Kroenke et al.,
2001) is a brief measure of depressive symptoms, the cut-off for
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“caseness” is a score of ≥10. The Generalized Anxiety Disorder Scale 7-
item version (GAD-7; Spitzer et al., 2006) is a measure of generalised
anxiety disorder symptoms with cut-off for “caseness” of ≥8. Addi-
tional information on phobias was collected by the three IAPT phobia
scale items (NHS Digital, 2017) and functional impairment was mea-
sured using the Work and Social Adjustment Scale (W&SAS:
Mundt et al., 2002).
2.4. Procedure
Patients completed the self-report symptom measures before every
treatment session either by using a secure online portal or by com-
pleting them on a pen-and-paper version and handing the completed
questionnaires to their clinicians who then entered the scores directly
into the electronic patient record system. Analyses were conducted
using these sessional data.
2.5. Plan of analysis
In distributions with sparse data-points beyond the mean there is a
risk that growth curve models can be distorted (Lutz et al., 2005). In
this dataset the mean was 10.9 sessions (SD = 4.31) including the
baseline assessment, so an upper limit of 13 time points was used in-
cluding a baseline assessment and 12 therapy sessions.
The first stage of analysis was to identify the average expected re-
sponse curve for the included sample of patients using latent growth
curve analysis (LGC), before identifying distinct sub-groups of patients
with differing forms of change using latent class growth analysis
(LCGA). LGC methods are used to estimate the mean trajectory of
change by pooling all individuals within a sample, incorporating
within-person variability (Curran et al., 2010). LGCA is a cluster ana-
lytic extension of LGC which categorises individuals with similar pat-
terns of change into subgroups (Lutz et al., 2014). The initial LGC was
performed separately for the PHQ-9 and GAD-7; models were built
fitting linear and quadratic curves, and by including/excluding residual
correlations as a time-varying factor. Model fits were compared using
the Comparative Fit Index (CFI) and Tucker-Lewis Index (TFI), along-
side the root mean square of error of approximation (RMSEA) and the
standardised root mean square residual (SRMR) (Berlin et al., 2014;
Geiser, 2013; Schermelleh-Engel et al., 2003).
LCGA models were compared using the following model fit statis-
tics: the Vuong-Lo-Medell-Rubin Likelihood Ratio Test (VLMR-LRT;
Lo et al., 2001), the Akaike Information Criterion (AIC), Bayesian In-
formation Criterion (BIC) and entropy values. The VLMR-LRT is a
comparison between one model with K-classes, and the K-1 model, with
a p-value < 0.05 indicating that the K model fits the data better than
the K-1 model. Lower AIC and BIC values for one model compared to
another indicate better model fit, whereas higher entropy values in-
dicate higher accuracy in classification for the model.
As there were no prior hypotheses on the number of classes, the
LCGA was first conducted with a two-class model, assessing fit statistics
and increasing the number of classes until the VLMR-LRT became non-
significant or any of the AIC or BIC values increased compared to the
previous class solution, as is standard for GMM/LCGA methods (Geiser,
2013; Musliner et al., 2016). Following convention with GMM models,
each class had to contain at least 5% of the sample for it to be con-
sidered meaningful and numerically stable (Gueorguieva et al., 2011;
Spinhoven et al., 2016).
A large number of IAPT patients are expected to be prescribed
psychotropic medications (HSCIC, 2014) which may impact symptom
change throughout therapy. Therefore, as a secondary analysis the data
were split based on medication status at baseline and the best fitting
trajectory class solution was modelled on those prescribed medications
and those not prescribed medications at baseline.
Finally, multinomial logistic regression models were fitted in order
to test associations between the different trajectory classes and patient
data routinely collected during the baseline assessment sessions, to
consider the possibility of predicting trajectory class membership pre-
treatment. Data on each patient's diagnosis/’problem descriptor’ were
included as potential predictors. IAPT services collect this information
in order to match patients to evidence-based treatments for specific
disorders (e.g. trauma-focused CBT for post-traumatic stress disorder)
(Clark et al., 2018). Due to distributions of those with each specific
problem descriptor, following convention from previous publications
using IAPT data from these services (e.g. Buckman et al., 2018a) the
problem descriptors were grouped in the following way: firstly, all
unipolar depressive disorders were grouped together (32.18% of the
included sample); then distinct categories were used for mixed anxiety
and depressive disorder (13.59%), generalized anxiety disorder
(9.08%), obsessive compulsive disorder (5.58%), and posttraumatic
stress disorder (4.01%). All phobic anxiety conditions and panic dis-
order were grouped together (10.36%), given the low numbers in each
category and the routine collection of symptom data related to these
disorders with the IAPT phobias scales. Finally, two separate categories
were used to denote disorders for which there are not established
treatment protocols in IAPT services and for which there are not
symptom measures used routinely across all IAPT services (see
Clark, 2018). One category was labelled “severe mental illness” (2.46%
of the sample) and included psychotic conditions including bi-polar
disorder (1.05% of the full sample), schizophrenia (0.46%) and per-
sonality disorders (0.96%). These conditions were grouped together
due to the likely involvement of additional services and clinicians (e.g.
Psychiatrists) in their care. Finally, an “other” category (5.33% of the
sample) was created from all remaining conditions for which there are
no IAPT treatment protocols and for which there was limited re-
presentation to adequately model the specific disorders (e.g. alcohol use
disorders [0.30%], eating disorders [0.36%], somatoform disorders
[1.21%], bereavement [1.66%] and adjustment disorder [1.80%]).
2.6. Missing data, software and packages
LCG and LCGA modelling was performed using Mplus version 7
(Muthén and Muthén, 2012), all regression models were built using
Stata version 15 (StataCorp, 2017).
For LCG and LCGA analyses, missing PHQ-9 and GAD-7 data were
handled using Full Information Maximum-Likelihood through the
Expectation Maximization (EM) algorithm (Dempster et al., 1977) as
standard in Mplus. Missing data on potential baseline predictors of
PHQ-9 and GAD-7 trajectory classes were imputed using multiple im-
putation with chained equations using the “ICE” package (Royston and
White, 2011).in Stata. All imputation models used the complete data on
baseline PHQ-9, GAD-7, W&SAS and the IAPT phobia scales, along with
age, gender, ethnicity, and diagnosis. All variables had less than 20%
missing data making them eligible for imputation and all imputation
models were run 100 times (Royston and White, 2011). The multi-
nomial regressions of baseline variables against the PHQ-9 and GAD-7




Demographic and symptom scores at assessment of the 4394 pa-
tients who met inclusion criteria are presented in Table 1. The mean
number of treatment sessions attended was 10.56 (SD 4.29). The vast
majority (92%) of patients received at least one session of CBT, whereas
counselling was received by only 12.06% of patients, and IPT by 1.66%
of the sample. All treatments were therefore considered together as
High intensity interventions, rather than conducting sub-analyses on
specific modalities of intervention.
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3.2. Trajectories of symptom change
In the first stage of the analysis, the mean latent growth curve was
plotted to estimate the expected response curve on both the PHQ-9 and
GAD-7 for the full sample. Model fit statistics are displayed in supple-
mentary table S1. Findings indicated that a linear LGC displayed poor
model fit, with CFI and TFI scores below 0.95 for both symptom mea-
sures. The introduction of a quadratic factor greatly improved the
model fit for both the PHQ-9 (CFI = 0.963, TFI = 0.965) and GAD-7
(CFI = 0.96, TFI = 0.962). The inclusion of correlated residuals re-
sulted in excellent model fit for both measures (PHQ: CFI = 0.988,
TFI = 0.987; GAD: CFI = 0.987, TFI = 0.985). The final model tra-
jectories for the PHQ-9 and GAD-7 are presented in Fig. 1 and labelled
the “Growth curve (full sample)”, and the growth parameter statistics
(mean and 95% confidence intervals) are presented in supplementary
table S2. The form of change for both symptom measures indicated a
sustained decrease in symptom scores that appeared to slightly level-
out as the number of sessions increased.
In the next stage of analysis, LCGA was performed on both measures
to identify distinct trajectories beyond the expected response curves. As
the LGC analysis identified the model with a quadratic curve and cor-
related residuals as the best fitting, LCGA was performed using this
model specification. Model fit statistics comparing the LGCA of PHQ-9
and GAD-7 are presented in Supplementary material table S3. Model fit
of the LCGAs using the parameters stated above led to a 4-class solution
for PHQ-9 symptom change and a 5-class solution for GAD-7 symptom
change. Growth parameter statistics for the identified trajectories are
presented in supplementary table S4.
The identified curves are presented in Fig. 1 alongside the pre-
viously identified mean growth curve and the classes can be described
as:
PHQ-9:
*Class 1 – Moderate-to-severe pre-treatment, slow initial response,
large response later in treatment.
*Class 2 – Moderate-to-severe pre-treatment, limited or no response
to treatment.
*Class 3 – Moderate severity pre-treatment, early initial response,
levelling out.
*Class 4 – Moderate-to-severe pre-treatment, rapid early improve-
ment, levelling out.
GAD-7:
*Class 1 – Severe pre-treatment, slow initial response, large response
later in treatment.
*Class 2 – Severe pre-treatment, limited or no response to treatment.
*Class 3 – Moderate-to-severe pre-treatment, early initial response,
levelling out.
*Class 4 – Mild pre-treatment, early initial response, levelling out.
*Class 5 – Moderate-to-severe pre-treatment, limited or no response
to treatment.
Differentiation in depressive symptom change trajectories between
patients in Class 1 (slow initial response, large response later in treat-
ment) and Class 2 (limited or no response to treatment) appears to
occur at around session four with clear differentiation in the trajectories
by session six, rather than by session three (as is often reported).
Patients in Class 4 (rapid improvement) show almost immediate and
sustained response to treatment, representing a group of patients for
whom HI treatments can be very effective, and they are distinguishable
from patients in the other classes by session 1. The largest class of pa-
tients (Class 3; early initial response) has the lowest intercept value
(pre-treatment PHQ-9 score), and are distinguishable from those in the
other three classes before treatment has begun, and go on to show a
reasonable decrease in depression symptoms, which is similar to the
mean growth curve of the full sample.
Of the change in anxiety symptoms, GAD-7 Class 1 shares character-
istics with PHQ-9 Class 1, in that they have a high pre-treatment score,
show limited initial change which gradually increases as treatment ses-
sions continues, and appear distinguishable from the other GAD-7 classes
by treatment session 2. Class 2 (Limited response) was similar to PHQ-9
Class 2, both could be defined as non-responders to treatment, with the
GAD-7 Class 2 group distinguishable from the other 4 classes at session 2.
There was less overlap between GAD-7 classes 1 and 2 compared to PHQ-9
classes 1 and 2, indicating that these GAD-7 classes are distinguishable
earlier in therapy than the PHQ-9 classes. The GAD-7 Class 5 appears to be
an additional non-responding group of patients, and are differentiated
from GAD-7 Class 2 by a lower pre-treatment GAD-7 score. GAD-7 Classes
3 and 4 both appear to be sub-groups of patients who show early initial
response to treatment that levels off over time; they are distinguisable
from each other pre-treatment, as Class 3 has a considerably higher pre-
treatment GAD-7 score than those in Class 4. These two trajectory classes
appear to represent lower and higher initial severity versions of PHQ-9
Class 3, although the initial slope of change appears larger in the GAD-7
classes. PHQ-9 Class 4 (rapid response to treatment) does not appear to
have a complimentary Class in the GAD-7 analysis, and may indicate that
sudden gains are less frequent for anxiety symptoms than depressive
symptoms in patients receiving HI IAPT therapies.
The co-occurrences of PHQ-9 and GAD-7 classes within the sample
were also explored (see Supplementary material table S5). The largest
Table 1
Descriptive statistics.
Characteristic Category n %
Gender Female 2783 63.34
Male 1538 35.00
Missing 73 1.66






Prescribed medication No 1651 37.57
Yes 1867 42.49
Missing 876 19.94
Diagnosis Depression 1414 32.18










Phobic anxiety & Panic 455 10.36
Severe mental illness (SMI) 108 2.46
Other 234 5.33
Missing 766 17.43
Characteristic n Mean (SD)
Age at referral 4393 38.49
(12.98)
PHQ-9 score 4394 16.41 (5.65)
GAD-7 score 4394 14.53 (4.43)
W&SAS score 4347 21.64 (9.22)
Social Phobia Score 4354 3.53 (2.64)
Agoraphobia Score 4352 3.03 (2.81)
Specific Phobia Score 4350 2.67 (2.81)
Number of sessions 4394 10.56 (4.29)
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combinations (34%, n=1484) were for the early initial improvement
groups, whereby 20.66% of patients (n= 908) were members of PHQ-9
Class 3 and GAD-7 Class 3, and 13.11% (n=576) were members of
PHQ-9 Class 3 and GAD-7 Class 4. There was also a large number of
individuals who were members of limited response classes on both
measures (PHQ-9 Class 2, and GAD-7 Classes 2 or 5), which included
nearly 27% (n=1170) of the sample, implying that the lack of re-
sponse in symptoms on one measure was likely to be reflected by a lack
of response on the other.
There were no differences in the form of the trajectories of de-
pressive symptom change between those prescribed (n=1867) and not
prescribed (n=1651) medications at baseline, the only difference were
that those not prescribed had slightly lower intercept values than those
prescribed medications (Supplementary Fig. 1a & b). For anxiety
symptom change intercepts were also higher among those prescribed
compared to those not prescribed medications. The form of the trajec-
tories for those not prescribed medications was similar to whole sample
irrespective of medication status (Supplementary Fig. 1c & d), however
for those that were prescribed medications the Class 1 showed a more
rapid initial response and lower GAD-7 endpoint, and Class 5 showed a
gradual decline in symptoms rather than a lack of response.
3.3. Baseline variables associated with trajectories
Associations between baseline patient characteristics and their
estimated PHQ-9 and GAD-7 trajectory class (respectively) were ana-
lysed in multinomial regression models. Table 2 (PHQ-9) and Table 3
(GAD-7) present odds ratios (OR), 95% confidence intervals (CI) and p-
values. Relative to being in PHQ-9 trajectory Class 2 (non-responders):
the probability of being in PHQ-9 trajectory Class 1 was higher with
higher baseline PHQ-9 scores and lower baseline GAD-7 scores. The
probability of being in PHQ-9 trajectory Class 3 relative to class 2 was
lower with: lower baseline PHQ-9 scores; lower GAD-7 scores; lower
WSAS scores, and lower scores on the IAPT phobia scale items on social
phobia and specific phobias; the probability was higher if individuals
had a diagnosis of GAD or “Other” diagnoses relative to depression. The
probability of being in PHQ-9 trajectory Class 4 compared to Class 2
was higher: with higher PHQ-9 scores; lower WSAS scores; lower scores
on the IAPT phobias scale items on social phobia and specific phobias
and was higher for those diagnosed with Phobic Anxiety or Panic Dis-
order, or “Other” diagnoses relative to depression.
Turning to the results for the GAD-7: relative to being in GAD-7
trajectory class two (non-responders), the probability of being in Class 1
was higher with: lower PHQ-9 scores; lower GAD-7 scores; lower scores
on the phobias scale items on social phobia, and specific phobias. The
probability of being in GAD-7 trajectory Class 3 compared to Class 2
was higher with lower: PHQ-9 scores; GAD-7 scores; WSAS scores;
scores on the three IAPT phobia scale items; it was also lower if diag-
nosed with OCD relative to depression. The probability of being in
GAD-7 trajectory Class 4 was higher with lower PHQ-9 scores, lower
Fig. 1. PHQ-9 and GAD-7 trajectory classes.
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GAD-7 scores, lower WSAS scores, lower scores on the three IAPT
phobia scales, and if diagnosed with “Other” relative to depression.
Finally, the probability of being in GAD-7 trajectory Class 5 relative to




This study identified distinct trajectories of change both for symp-
toms of depression and anxiety in a relatively large cohort of patients
receiving high-intensity psychological treatments in two UK psycholo-
gical treatment services. We found four distinct trajectories of change in
depressive symptoms and five distinct trajectories for symptoms of
anxiety. Where classes across the symptom domains were similar there
was a moderately high degree of overlap such that patients that ex-
perienced high degrees of symptomatic change on the PHQ-9 also ex-
perienced high degrees of change on the GAD-7. Although like previous
studies we found some evidence for a clear distinction between patients
being “on-track” or “not-on-track” in psychological therapies by session
three, we also found one trajectory class of depression symptoms that
showed slow initial response but then rapid later response from session
six onwards. In addition, a number of the classes were distinguishable
Table 2
Associations between baseline characteristics and PHQ-9 trajectory classes 1, 3 and 4 relative to class 2 (non-responders).
Baseline predictor PHQ-9 Class 1 RR(95%CI) & p-value PHQ-9 Class 3 RR(95%CI) & p-value PHQ-9 Class 4 RR(95%CI) & p-value
Age 0.88(0.68–1.14), p = .332 1.00(0.99–1.00), p = .157 1.00(0.99–1.01), p = .405
Gender
Female 0.98(0.77–1.23), p = .832 1.04(0.87–1.23), p = .677 0.96(0.77–1.19), p = .690
Male 1.0 1.0 1.0
Ethnicity
White 1.0 1.0 1.0
Not white 0.94(0.72–1.24), p = .676 0.82(0.66–1.02), p = .069 0.90(0.69–1.17), p = .420
Primary Diagnosis
Depression 1.0 1.0 1.0
Mixed A&D 1.21(0.86–1.69), p= .275 1.02(0.77–1.33), p= .911 0.99(0.70–1.38), p=.935
GAD 0.71(0.41–1.24), p= .228 1.57(1.23–2.19), p= .008 1.35(0.87–2.09), p=.176
OCD 1.13(0.67–1.92), p= .644 1.00(0.67=1.48), p= .990 1.04(0.60–1.78), p=.895
PTSD 1.03(0.62–1.72), p= .622 0.95(0.61–1.47), p= .813 1.05(0.63–1.74), p=.847
Phobic Anxiety or Panic 1.11(0.73–1.71), p= .622 1.34(0.97–1.84), p= .073 1.89(0.13–2.81), p=.002
Severe MI 0.78(0.37–1.64), p= .514 1.29(0.76–2.19), p= .337 1.15(0.60–2.20), p=.680
Other 0.64(0.33–1.25), p= .188 1.65(1.10–2.58), p= .015 1.65(1.02–2.66), p=.040
Psychotropic Medications
Prescribed 1.13(0.87–1.46), p= .356 0.89(0.73–1.07), p= .219 0.80(0.62–1.02), p=.066
Not prescribed 1.0 1.0 1.0
PHQ-9 Score 1.04(1.00–1.07), p= .028 0.81(0.80–0.83), p< .001 1.12(1.08–1.15), p<.001
GAD-7 Score 0.97(0.93–1.00), p= .047 0.93(0.91–0.95), p< .001 0.97(0.94–1.00), p= .031
WSAS score 1.00(0.98–1.01), p= .706 0.97(0.96–0.98), p< .001 0.96(0.95–0.98), p<.001
Social Phobia Score 0.96(0.91–1.01), p= .128 0.92(0.88–0.96), p< .001 0.91(0.86–0.95), p<.001
Agoraphobia Score 0.99(0.94–1.05), p= .850 0.98(0.94–1.02), p= .308 0.97(0.92–1.02), p=.237
Specific Phobia Score 0.96(0.92–1.01), p= .135 0.95(0.92–0.99), p= .007 0.90(0.86–0.94), p<.001
Table 3
Associations between baseline characteristics and GAD-7 trajectory classes 1, 3, 4, and 5, relative to class 2 (non-responders).
Baseline predictor GAD-7 Class 1 RR(95%CI) & p-value GAD-7 Class 3 RR(95%CI) & p-
value
GAD-7 Class 4 RR(95%CI) & p-
value
GAD-7 Class 5 RR(95%CI) & p-
value
Age 0.99(0.98–1.00), p= .258 1.0(0.99–1.01), p= .992 1.0(0.99–1.01), p= .897 1.0(0.99–1.01), p= .862
Gender
Female 0.98(0.76–1.27), p= .892 0.83(0.67–1.03), p=.093 0.78(0.6–1.01), p= .061 0.91(0.73–1.12), p= .377
Male 1.0 1.0 1.0 1.0
Ethnicity
White 1.0 1.0 1.0 1.0
Not white 0.87(0.65–1.18), p= .372 0.97(0.76–1.25), p=.820 0.76(0.55–1.05), p= .094 1.03(0.81–1.32), p= .787
Primary Diagnosis
Depression 1.0 1.0 1.0 1.0
Mixed A&D 1.22(0.84–1.79), p= .297 1.05(0.76–1.44), p=.761 0.93(0.62–1.4), p= .742 1.28(0.93–1.74), p= .128
GAD 1.47(0.94–2.30), p= .093 1.05(0.71–1.56), p=.81 1.18(0.72–1.93), p= .51 0.95(0.63–1.43), p= .802
OCD 1.20(0.72–2.00), p= .474 0.62(0.39–0.98), p=.039 0.55(0.3–1), p= .052 0.81(0.51–1.28), p= .362
PTSD 1.16(0.67–2.00), p= .596 0.68(0.41–1.13), p=.135 0.87(0.44–1.7), p= .682 0.81(0.5–1.31), p= .384
Phobic Anxiety or Panic 1.32(0.84–2.08), p= .228 1.29(0.89–1.88), p=.184 1.26(0.78–2.03), p= .349 1.09(0.74–1.61), p= .656
Severe MI 1.28(0.63–2.62), p= .495 0.8(0.41–1.58), p= .524 1.3(0.58–2.91), p= .528 1.09(0.58–2.07), p= .783
Other 0.95(0.48–1.88), p= .890 1.62(0.99–2.65), p=.057 1.87(1.02–3.42), p= .042 1.62(0.98–2.67), p= .06
Psychotropic Medications
Prescribed 0.84(0.64–1.10), p= .196 1.0(0.79–1.26), p= .987 0.95(0.71–1.28), p= .732 1.01(0.79–1.29), p= .926
Not prescribed 1.0 1.0 1.0 1.0
PHQ-9 Score 0.96(0.93–0.99), p= .005 0.93(0.91–0.96), p<.001 0.92(0.89–0.95), p< .001 0.98(0.95–1), p= .08
GAD-7 Score 0.94(0.90–0.99), p= .012 0.69(0.66–0.71), p<.001 0.55(0.52–0.57), p< .001 0.71(0.68–0.74), p< .001
WSAS score 0.98(0.97–1.00), p= .057 0.96(0.95–0.97), p<.001 0.95(0.93–0.96), p< .001 0.98(0.96–0.99), p< .001
Social Phobia Score 0.94(0.89–0.99), p= .026 0.93(0.89–0.98), p=.004 0.92(0.87–0.98), p= .007 0.96(0.91–1.01), p= .082
Agoraphobia Score 1.01(0.96–1.07), p= .668 0.94(0.9–0.99), p= .011 0.89(0.83–0.94), p< .001 0.98(0.94–1.03), p= .432
Specific Phobia Score 0.93(0.89= 0.98), p= .004 0.94(0.9–0.98), p= .004 0.94(0.89–0.99), p= .021 0.97(0.93–1.01), p= .172
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at baseline considering only initial depression or anxiety symptom
scores.
4.2. Interpretation
The overall treatment responses we observed for both depressive
and anxiety symptoms were broadly similar to patterns identified in
previous studies (Cuijpers et al., 2013; Kopta et al., 1994). However,
when LCGA was used to explore sub-groups of patients based on their
symptom patterns over time, we found distinct trajectories of change
that differed considerably to the mean response curve. Using these
different trajectory classes to inform clinicians of their patients’ pro-
gress against the expected response curves might allow for more de-
tailed monitoring and more accurate predictions of treatment out-
comes. Further, providing “on-track” or “not-on-track” information
based on these trajectories might allow for more informed treatment
related decision making and could potentially lead to greater benefits
for patients than has been found when basing such feedback on a single
growth curve (e.g. Lambert et al., 2001a). This information could be
fed-back to clinicians via the electronic health record system giving
clinicians and patients an opportunity to consider changing their
treatment plan and, with more accurate predictions of treatment out-
come, might further inform discussions around extended treatment or
relapse prevention interventions (Buckman et al., 2018c).
An interesting finding was that one group of patients showed slow
initial response to therapy in their depressive symptoms but later, rapid
and sustained improvement, from around session six onwards (PHQ-9
Class 1). There are a number of potential reasons for this: perhaps those
in PHQ-9 Class 1 have more complex issues that may take longer to
address and affect symptomatic change than those in the early re-
sponding class (PHQ-9 Class 3). Alternatively, these patients may be
less engaged in the early stages of therapy as the therapeutic relation-
ship which gradually develops as therapy progresses.
If clinicians were able to identify patients who were following this
delayed response trajectory, then they might continue with their cur-
rent treatment plan rather than ending or changing treatment early due
to a lack of initial response. This finding goes against the current
“conventional wisdom” and findings from previous researchers
(Lambert, 2013) which suggests a lack of significant symptomatic im-
provement by the third therapy session is a signal to the clinician that
they should consider changing or stopping treatment. In addition, and
of potential utility, baseline characteristics were associated with a
higher likelihood of one trajectory over another, for example better
responding depressive symptom trajectories were associated with lower
depressive symptom severity, lower phobia scores and having GAD or
Panic/Phobic anxiety as the presenting problem. Patients in these sub-
groups could have their likely prognoses predicted pre-treatment
helping inform joint decision making about the potential best care
pathways for them. Other classes were distinguishable at session two,
slightly earlier than “conventional wisdom” suggests that accurate
predictions of prognosis may be made. Further, while previous studies
investigating trajectories of change in symptoms during psychological
therapies have focussed on single outcome measures (Lambert et al.,
2001b) this study identified statistically distinct classes of patients with
different trajectories of change in both depression and anxiety symp-
toms, measured on two different outcome measures, which may be
more clinical informative than a single outcome measurement alone.
The trajectories identified in the current analysis have both simi-
larities and differences to previous studies using similar methods in
datasets of change in symptoms during acute treatment. A previous
analysis of secondary care patients receiving psychological treatment
identified five trajectories of symptom change, over the first six sessions
of treatment (Stulz et al., 2007), suggesting a similar number of distinct
forms of change in alternative datasets. The main differences between
the trajectories presented in this paper and that of Stulz and colleagues
are that the current trajectories indicated more patients with reductions
in symptoms, which may be due to the use of NICE-adherent treatments
in IAPT which have proven effectiveness as well as the inclusion of
more time points (12 sessions). It is of interest that the current study
identified a ‘late responding’ group of patients based on depression
symptom change, this group appears to match a group of “one-step”
responders identified in a randomised control trial of cognitive therapy
for depression (Vittengl et al., 2013, 2016). The prevalence of this
trajectory was comparable between samples (13% vs 16%) and may
indicate a sub-group of patients that exist across a range of settings.
Further research to identify this group early on during the therapeutic
process could support clinical decision making.
Findings from the current analysis differed from findings by
Gueorguiva et al. (2011) who identified only two trajectories from a
dataset from a clinical trial of antidepressant treatment. It is possible
that the sample used in this analysis is not comparable to the sample
used by Gueorguieva et al. (2011) and the more homogenous sampling
used in controlled trials may result in less variation in trajectories, or
trajectories of change for pharmacological interventions may just differ
to those for psychological treatments. Future research would benefit
from exploring differences in trajectories between routine treatment
datasets and clinical trial datasets, as well as different interventions
delivered.
4.3. Clinical implications
This paper presents a method of identifying differential responders
to psychological treatment for depression and anxiety disorders, using
routinely collected patient data. The identification of a sub-population
of patients that show slow initial response followed by rapid improve-
ment in depressive symptoms later in therapy, would suggest that
continuing treatment beyond the first three sessions even when limited
change has been observed could result in a positive outcome from
treatment for those in that class. Information about likely trajectory of
symptom change, when combined with the use of baseline patient
characteristics that can predict likely trajectory class could be used to
support clinical decision making and lead to improved treatment out-
comes. Being able to identify likely non-responders to therapy at the
point of a baseline assessment has several potential implications.
Firstly, this might inform joint clinician-patient decision making on
whether or not to begin therapy or to consider other treatment options.
In addition, if a patient started psychological therapy but their symp-
toms showed limited change and they were seemingly continuing along
the expected trajectory of Class 2, this would be useful information to
inform decisions on changing treatment or considering adjunctive op-
tions.
4.4. Limitations
The dataset used for this analysis comes from two IAPT services in
the UK and therefore further analysis with data from additional services
would be of value to determine whether these findings are general-
izable. Although the baseline characteristics of the patients that make
up the present sample are similar to those of other samples of IAPT
services from the same time period (e.g. Gyani et al., 2011; Richards
and Suckling, 2009), with similar mean PHQ-9 and GAD-7 symptom
severity and age, services may differ in treatment decision making
practices resulting in differences in patients receiving treatment at high
and low intensity across services. All patients in the analysis received
High Intensity IAPT interventions which are structured to deliver evi-
dence-based treatment protocols (Clark, 2018). However, information
on treatment protocol adherence was not available in the current da-
taset. Future analyses comparing protocol adherence to trajectories of
symptom change could further our ability to use symptom measures to
inform clinical decision making. The GAD-7 is limited by its focus just
on primarily generalised anxiety symptoms, and other anxiety disorder
specific measures may give a more nuanced picture of trajectories of
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change by different anxiety diagnoses. In addition, data on problem
descriptor in IAPT comes from a clinician's judgement of the primary
presenting problem and may not have the same prognostic value if
clinicians were to use a formalised diagnostic interview. Therefore,
results regarding the probability of trajectory class membership dif-
fering by problem descriptor must be treated with caution.
The results of the multinomial analyses indicated that compared
with the trajectory class of non-responding patients, responding tra-
jectories were associated with lower baseline severity scores and better
social functioning. However, the multinomial models identified limited
variables (e.g. functional impairment, symptom severity) that were
associated with being in the non-responding class and the late re-
sponding PHQ-9 class. This may suggest that processes occurring during
treatment, such as the nature of therapeutic alliance (Falkenström et al.,
2016), may better explain the different likelihood of patients following
these trajectories than relying solely on routine patient data collected at
baseline. The inclusion of more baseline characteristics that may be
associated with outcomes, for example patient treatment preference or
information on previous treatments (Cohen and DeRubeis, 2018) that
may be available in alternative datasets may also yield better predic-
tions of trajectory membership. Lastly, around 50% of patients pro-
viding data had been prescribed psychotropic medication at the time of
assessment, but no information was available on the details of their
prescription nor on their adherence to this. Although being prescribed
medication was not significantly associated with any trajectory, in-
cluding data on adherence to medication could be informative and
therefore of value to explore in future research. It is noteworthy that
trajectories of change for depressive symptoms were very similar
whether or not patients were prescribed medication at baseline, and
two classes of anxiety symptom change showed greater degrees of re-
sponse among those prescribed medications at baseline.
5. Conclusions
This study adds to the literature identifying distinct forms of change
in symptoms during treatment for common mental disorders by using
growth mixture modelling techniques in a large sample of patients re-
ceiving psychological therapy in routine treatment services. The sample
size benefits allow for reliable detection of distinct classes and support a
number of previous findings in other settings. We identified a number
of distinct trajectories of change in symptom scores, indicating different
prognoses following treatment for distinct subgroups of those receiving
psychological therapies. Most of these trajectories could be differ-
entiated by the third session of treatment, consistent with previous
research. However, one depression symptom trajectory showed slow
initial response followed by a rapid later improvement in symptoms.
Further, a number of patient characteristics measured pre-treatment
were associated with greater likelihood of certain trajectories, giving
the opportunity to consider likely prognosis before treatment begins.
The consideration of these trajectories could be used to inform clin-
icians about the likely level of symptoms at the end of treatment,
helping to differentiate when changes to a treatment regimen may be
required.
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